AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 31 min read$AMGN

Amgen boosts 2026 guidance following Q3 beats

Amgen raised its 2026 revenue and profit forecasts after Q3 earnings and revenue surpassed expectations. Revenue is now projected at $38.9B-$39.7B, up from $38B-$39.4B. Non-GAAP EPS is expected to be $22.90-$23.70, compared to the previous range of $22.30-$23.50.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 11:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The guidance increase is a fresh, material disclosure for a large‑cap biotech, likely moving the stock.

02

Market read

First report of Amgen's 2026 guidance upgrade; actionable for traders ahead of market open.

03

What to watch

Potential pipeline risks or upcoming regulatory decisions could temper the upside.

Relevance 8/10Novelty 9/10Timing: pre‑market tomorrow

Background

Amgen's Q3 results beat expectations, prompting the guidance lift.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen raised its 2026 revenue guidance to $38.9B‑$39.7B and EPS guidance to $22.90‑$23.70, up from prior ranges.

Expected impact

upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Large‑cap biotech with guidance lift of several hundred million dollars; market typically reacts positively to upward guidance.

Market effects

Sector

Biotech sector may see modest uplift as a leading peer signals stronger demand.

Regional

U.S. markets could open slightly higher on biotech optimism.

Global

Limited to investors tracking large‑cap pharma/biotech earnings.

Counterpoint

What could challenge this read

If guidance already priced in, the upgrade may be a short‑term sell‑off on profit‑taking.

Key entities

  • company
    Amgen

    U.S. biotech firm reporting Q3 results and raising 2026 guidance.

Read at source← All news

StoryAmgen posts Q3 2026 earnings, lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min